Barry D. Quart
2015
In 2015, Barry D. Quart earned a total compensation of $6.5M as Chief Executive Officer at Heron Therapeutics, a 67% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $333,697 |
|---|---|
| Option Awards | $5,582,675 |
| Salary | $551,565 |
| Other | $7,950 |
| Total | $6,475,887 |
Quart received $5.6M in option awards, accounting for 86% of the total pay in 2015.
Quart also received $333.7K in non-equity incentive plan, $551.6K in salary and $8K in other compensation.
Rankings
In 2015, Barry D. Quart's compensation ranked 1,105th out of 13,638 executives tracked by ExecPay. In other words, Quart earned more than 91.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,105 out of 13,638 | 92nd |
Division Manufacturing | 393 out of 5,190 | 92nd |
Major group Chemicals And Allied Products | 139 out of 1,854 | 93rd |
Industry group Drugs | 106 out of 1,528 | 93rd |
Industry Pharmaceutical Preparations | 86 out of 1,182 | 93rd |
Source: SEC filing on April 29, 2016.
Quart's colleagues
We found four more compensation records of executives who worked with Barry D. Quart at Heron Therapeutics in 2015.
News
Heron Therapeutics CEO Craig Collard receives $11M in 2023
April 29, 2024
Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
May 1, 2023
Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
April 25, 2022
Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
April 22, 2021
Heron Therapeutics CEO Barry Quart's 2019 pay slips 2% to $5.9M
April 23, 2020